Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Liabilities and Shareholders Equity (2019 - 2025)

aTYR PHARMA's Liabilities and Shareholders Equity history spans 7 years, with the latest figure at $93.0 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 3.95% year-over-year to $93.0 million; the TTM value through Dec 2025 reached $398.4 million, down 2.26%, while the annual FY2025 figure was $93.0 million, 3.95% down from the prior year.
  • Liabilities and Shareholders Equity reached $93.0 million in Q4 2025 per ATYR's latest filing, down from $106.7 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $136.8 million in Q1 2023 to a low of $49.0 million in Q2 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $102.9 million, with a median of $103.2 million recorded in 2022.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 198.34% in 2021, then decreased 26.75% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $115.5 million in 2021, then fell by 17.09% to $95.8 million in 2022, then increased by 25.96% to $120.7 million in 2023, then dropped by 19.75% to $96.8 million in 2024, then fell by 3.95% to $93.0 million in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Liabilities and Shareholders Equity are $93.0 million (Q4 2025), $106.7 million (Q3 2025), and $101.5 million (Q2 2025).